Diligence memo · auto-generated · as of July 2, 2026
Ionetix Corp
Ionetix Corp looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Ionetix Corp operates in Pharmaceuticals, based in Lansing.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ionetix Corp has raised $77M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $37M on 2018-12-14.
Most recent recorded round closed around 2024-08-09.
Valuation (modeled)modeled
Provath models Ionetix Corp at approximately $104M (range $32M–$182M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.80× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era. Within the normal band (80% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 25 months.
Last raise 23 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 2.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 88% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 55% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
18 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.